NasdaqGS:WGSHealthcare
GeneDx (WGS) Valuation Check as JAMA Highlights GUARDIAN Newborn Genomic Screening Study
GeneDx Holdings (WGS) just saw its GUARDIAN newborn genomic screening study highlighted in JAMA’s Research of the Year, a credibility boost that could quietly reshape how investors view its long term growth runway.
See our latest analysis for GeneDx Holdings.
The recognition has landed while momentum is already strong, with GeneDx’s share price up 76% year to date and an 81% total shareholder return over the last year, signaling investors are steadily repricing its growth story.
If this kind...